CN104661670A - 用于治疗动脉粥样硬化的方法 - Google Patents

用于治疗动脉粥样硬化的方法 Download PDF

Info

Publication number
CN104661670A
CN104661670A CN201380049785.5A CN201380049785A CN104661670A CN 104661670 A CN104661670 A CN 104661670A CN 201380049785 A CN201380049785 A CN 201380049785A CN 104661670 A CN104661670 A CN 104661670A
Authority
CN
China
Prior art keywords
simvastatin
arg
lovastatin
peptide
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380049785.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·特拉维斯·威尔逊
马克·班伯格
布莱恩·布莱基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Priority to CN201910002871.XA priority Critical patent/CN110090304A/zh
Publication of CN104661670A publication Critical patent/CN104661670A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201380049785.5A 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法 Pending CN104661670A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910002871.XA CN110090304A (zh) 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261678992P 2012-08-02 2012-08-02
US61/678,992 2012-08-02
US201261695850P 2012-08-31 2012-08-31
US201261695807P 2012-08-31 2012-08-31
US61/695,807 2012-08-31
US61/695,850 2012-08-31
PCT/US2013/053007 WO2014022551A1 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910002871.XA Division CN110090304A (zh) 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法

Publications (1)

Publication Number Publication Date
CN104661670A true CN104661670A (zh) 2015-05-27

Family

ID=50028503

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380049762.4A Pending CN104768564A (zh) 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法
CN201380049785.5A Pending CN104661670A (zh) 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法
CN201910002871.XA Pending CN110090304A (zh) 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201380049762.4A Pending CN104768564A (zh) 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910002871.XA Pending CN110090304A (zh) 2012-08-02 2013-07-31 用于治疗动脉粥样硬化的方法

Country Status (8)

Country Link
US (5) US10201585B2 (enExample)
EP (6) EP2879688A4 (enExample)
JP (5) JP2015524439A (enExample)
CN (3) CN104768564A (enExample)
AU (4) AU2013296494B2 (enExample)
CA (2) CA2880643A1 (enExample)
HK (2) HK1210962A1 (enExample)
WO (2) WO2014022552A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
CN107666909A (zh) * 2014-11-10 2018-02-06 亚历山大·弗拉基米罗维奇·季科夫斯基 组合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2880643A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
EP4005582A1 (en) * 2012-10-22 2022-06-01 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
US11355245B2 (en) * 2016-05-03 2022-06-07 International Business Machines Corporation Identifying and ranking risk factors using trained predictive models
ES2871783T3 (es) * 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
EP3606938A1 (en) 2017-04-05 2020-02-12 Stealth BioTherapeutics Corp Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202005439D0 (en) 2020-04-14 2020-05-27 Aurigen Medical Ltd A device for occlusion of a left a trial appendage of a heart

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2002336959B2 (en) * 2001-08-10 2006-07-13 Novartis Ag Peptides that bind to atherosclerotic lesions
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
ES2694574T3 (es) * 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
SI3248613T1 (sl) 2005-07-18 2022-04-29 Seagen Inc. Konjugati beta-glukuronidni linker-zdravilo
WO2007089787A2 (en) 2006-01-30 2007-08-09 Israel Ben David Bryson Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients
WO2008026702A1 (fr) 2006-08-30 2008-03-06 Kyushu University, National University Corporation Composition pharmaceutique contenant une nanoparticule de statine encapsulée
US20090186832A1 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
EP2252312B1 (en) * 2008-02-07 2014-04-09 Cornell University Methods for preventing or treating insulin resistance
DK2464371T3 (en) 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
EP3040080A1 (en) 2010-03-15 2016-07-06 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
SG191219A1 (en) 2010-12-22 2013-07-31 Genentech Inc Anti-pcsk9 antibodies and methods of use
CA2880643A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.CHEN ET AL: "Mitochondria-Targeted Peptide MTP-131 Alleviates Mitochondrial Dysfunction and Oxidative Damage in Human Trabeclar Meshwork Cells", 《INVESTIGATIVE OPHTHALMOLOGY&VISUAL SCIENCE》 *
SUSANNE ZADELAAR,ET AL: "Mouse Models for Atherosclerosis and Pharmaceutical Modifiers", 《ATHEROSCLEROSIS AND PHARMACEUTICS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107666909A (zh) * 2014-11-10 2018-02-06 亚历山大·弗拉基米罗维奇·季科夫斯基 组合物
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用

Also Published As

Publication number Publication date
AU2018202068A1 (en) 2018-04-19
WO2014022551A1 (en) 2014-02-06
AU2013296494B2 (en) 2018-04-26
HK1210953A1 (en) 2016-05-13
US20180339012A1 (en) 2018-11-29
AU2018202197A1 (en) 2018-04-26
JP2015529655A (ja) 2015-10-08
HK1210962A1 (en) 2016-05-13
US20180344797A1 (en) 2018-12-06
AU2013296493B2 (en) 2018-04-26
CA2880643A1 (en) 2014-02-06
EP2879688A4 (en) 2015-12-16
US10201585B2 (en) 2019-02-12
US20150283200A1 (en) 2015-10-08
WO2014022552A1 (en) 2014-02-06
CN110090304A (zh) 2019-08-06
US20200000870A1 (en) 2020-01-02
JP2015524439A (ja) 2015-08-24
EP3300740A1 (en) 2018-04-04
CN104768564A (zh) 2015-07-08
CA2880648A1 (en) 2014-02-06
AU2013296493A1 (en) 2015-02-26
US10188693B2 (en) 2019-01-29
EP3132800A1 (en) 2017-02-22
EP2879689A1 (en) 2015-06-10
EP2879689A4 (en) 2015-12-16
JP2018016637A (ja) 2018-02-01
JP2018012726A (ja) 2018-01-25
US20150157685A1 (en) 2015-06-11
AU2013296494A1 (en) 2015-02-26
JP2019108389A (ja) 2019-07-04
EP2879688A1 (en) 2015-06-10
EP3485897A1 (en) 2019-05-22
EP3662921A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
US20200000870A1 (en) Methods for treatment of atherosclerosis
US11376304B2 (en) Methods and compositions for the prevention and treatment of disease
JP6271785B2 (ja) 代謝性症候群を予防し又は治療するための方法
CN103830719A (zh) 用于进行冠状动脉旁路移植手术的方法
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
WO2014185952A1 (en) Methods for the prevention or treatment of left ventricle remodeling
HK40007041A (en) D-arg-2'6'-dmt-lys-phe-nh2 for decreasing statin side effects

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150527

RJ01 Rejection of invention patent application after publication